Cardiotoxicity induced by multiple myeloma therapies: mechanistic convergence across proteasome inhibitors, CAR-T, and bispecific antibodies [0.03%]
由多种治疗诱导的多发性骨髓瘤心脏毒性:蛋白酶体抑制剂、CAR-T和双特异性抗体之间的机制汇合
Arnav Ramnath Chatrathi,Krina Patel,Neeraj Saini et al.
Arnav Ramnath Chatrathi et al.
Cardiovascular toxicity has emerged as an important obstacle to realizing the complete clinical potential of contemporary therapies for multiple myeloma (MM), including proteasome inhibitors (PIs), chimeric antigen receptor T-cell (CAR-T) t...
Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry [0.03%]
来自亚太真实世界登记处的套细胞淋巴瘤巩固治疗演变和对生存影响的启示
Hyungwoo Cho,Koji Kato,Jason Yongsheng Chan et al.
Hyungwoo Cho et al.
Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms [0.03%]
TET2突变的克隆架构及其在髓系肿瘤中可能的双等位基因失活的影响
Yudi Zhang,Wei Wang,Qiaoli Li et al.
Yudi Zhang et al.
Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma [0.03%]
一线根除幽门螺杆菌治疗早期胃外黏膜相关淋巴组织淋巴瘤的II期前瞻性研究
Ming Yao,Xavier Cheng-Hong Tsai,Chung-Wu Lin et al.
Ming Yao et al.
Chronic myeloid leukemia: incorporation of recent advances into current treatment algorithms [0.03%]
慢性粒细胞白血病：将近期研究成果融入当前治疗路径
Fadi G Haddad,Hagop Kantarjian
Fadi G Haddad
Several approved and investigational BCR::ABL1 tyrosine kinase inhibitors (TKIs) and STAMP inhibitors are used for the treatment of chronic myeloid leukemia in chronic phase (CML-CP). In the frontline setting, multiple factors affect select...
Ultra-high-sensitivity next-generation sequencing-based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort [0.03%]
基于超高灵敏度的下一代测序的微小残留病灶预测强化治疗的老年急性髓系白血病患者的预后：来自ALFA-1200队列的结果
Augustin Boudry,Laurène Fenwarth,Raphaël Itzykson et al.
Augustin Boudry et al.
Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial [0.03%]
低剂量达沙替尼治疗慢性期老年费城染色体阳性慢性髓性白血病患者长期疗效：DAVLEC II期临床试验的延长随访结果
Hiroshi Ureshino,Kazunori Murai,Takashi Kumagai et al.
Hiroshi Ureshino et al.
Gene- and subtype-dependent prognostic impact of ras pathway mutations in acute myeloid leukemia: a cohort study of 2,500 patients [0.03%]
急性髓系白血病中RAS途径突变的基因和亚型依赖性的预后影响：2500名患者队列研究
Heng Shen,Yan Hui,Yuntao Liu et al.
Heng Shen et al.
Prevalence of monoclonal gammopathy of undetermined significance (MGUS) using a sensitive mass spectrometry assay in young individuals 10-49 years of age: a population-based study from the National Health and Nutritional Examination Survey [0.03%]
基于全国健康和营养调查的年轻单克隆免疫球蛋白血症患者流行病学研究：一种敏感的质谱检测方法在10-49岁人群中的应用
Shaji Kumar,David Murray,Dirk R Larson et al.
Shaji Kumar et al.
The prevalence of monoclonal gammopathy of undetermined significance (MGUS) increases with age, but the study of age of onset and the prevalence of MGUS in younger individuals has been limited by lack of sensitive serum protein testing meth...
Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma [0.03%]
针对中枢神经系统受累淋巴瘤患者的CD3xCD20双特异性抗体临床疗效
Karan L Chohan,Rina L Welkie,James Godfrey et al.
Karan L Chohan et al.